A recently published article in Newsweek discusses the groundbreaking advancements in genetic sequencing that are transforming cancer treatment. It highlights how technologies like whole genome sequencing (WGS) are enabling doctors to identify genetic mutations in tumors and personalize treatments for patients, including those with rare or difficult-to-treat cancers. One key example is the case of […]

Marco Ruella, MD, Gabrielle’s Angels grantee in 2014 and 2017 (Medical Advisory Board discretionary funding) and 2019 (Medical Research Award), assistant professor, medicine (hematology-oncology), Perelman School of Medicine; scientific director, Lymphoma Program, the Hospital of the University of Pennsylvania, discusses the implications of findings from a retrospective study evaluating access to and outcomes with commercial […]

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer. The studies – both conducted in patient samples and animal models – found that inhibiting […]

Gabrielle’s Angel Foundation grantee Grant Challen, PhD (MRA recipient in 2016 and The Mark Foundation for Cancer Research Collaborative Grant Recipient from 2023) from Washington University in St. Louis is one of the authors of a new paper published in Nature on January 16, 2025 examining the role of RSK1 in myeloproliferative neoplasms and secondary […]

Big news from Dana-Farber Cancer Institute regarding the FDA approval of revumenib for the treatment of relapsed acute leukemia! Gabrielle’s Angel Foundation funded Scott Armstrong, MD, PhD back in 2007 during the preliminary research of this project. These early efforts to understand how the cell makes use of menin, to explorations of the cell machinery […]

After an allogeneic stem cell transplant, a recipient’s body faces a daunting task: rebuilding the person’s blood-forming and immune systems from the ground up from a relatively small number of “seed” cells obtained from their donor. To achieve this, the donated cells must replicate again and again — and again.  It’s a cycle that might put […]

Exciting news out of Dana-Farber on a  the development of new menin-targeting agents that showed promise in clinical trials involving adults with acute myeloid leukemia (AML), one of the hardest-to-treat forms of leukemia. Scott Armstrong, MD, PhD, Gabrielle’s Angel Foundation Medical Research Award recipient in 2007 and current senior vice president for drug discovery and chief […]

With your support in 2023, we were able to fund 6 new individual researchers with grants of $225,000 each as well as co-funding with The Mark Foundation for Cancer Research 2 new collaborative research teams with grants of $500,000 each. Our grants are chosen by our outstanding Medical Advisory Board, assuring that the money that […]

Gabrielle’s Angel Foundation’s Medical Advisory Board recently selected 6 talented early career scientists to receive Medical Research Awards for a total of $1.35M in grants! Awards are $225,000 over a three year period. We are delighted to welcome these brilliant investigators to our Gabrielle’s Angels family! Stay tuned for spotlights on each grantee and their work throughout the rest of the […]

https://patch.com/new-jersey/newbrunswick/500k-grant-supports-exploration-therapies-rare-lymphomas

We are delighted to welcome Dr. Sarah Tasian to the Medical Advisory Board of Gabrielle’s Angel Foundation for Cancer Research! Sarah K Tasian, MD is a pediatric oncologist and physician-scientist at the Children’s Hospital of Philadelphia (CHOP) and an Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine who is interested in […]

From the lab of Gabrielle’s Angels grantee Iannis Aifantis – their latest work on peptide:MHC class I expression & degradation and the discovery of a novel protein complex potentially important for T cell recognition in cancer. Immune-checkpoint blockade has revolutionized cancer treatment, but some cancers, such as acute myeloid leukemia (AML), do not respond or […]